Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk

F. L. Wong, J. D. Boice Jr, D. H. Abramson, R. E. Tarone, R. A. Kleinerman, M. Stovall, M. B. Goldman, J. M. Seddon, N. Tarbell, J. F. Fraumeni Jr and F. P. Li
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Md 20892, USA.

CONTEXT: There is a substantial risk of a second cancer for persons with hereditary retinoblastoma, which is enhanced by radiotherapy. OBJECTIVE: To examine long-term risk of new primary cancers in survivors of childhood retinoblastoma and quantify the role of radiotherapy in sarcoma development. DESIGN: Cohort incidence study of patients with retinoblastoma followed for a median of 20 years, and nested case-control study of a radiation dose-response relationship for bone and soft tissue sarcomas. SETTING/PARTICIPANTS: A total of 1604 patients with retinoblastoma who survived at least 1 year after diagnosis, identified from hospital records in Massachusetts and New York during 1914 to 1984. RESULTS: Incidence of subsequent cancers was statistically significantly elevated only in the 961 patients with hereditary retinoblastoma, in whom 190 cancers were diagnosed, vs 6.3 expected in the general population (relative risk [RR], 30 [95% confidence interval, 26-47]). Cumulative incidence (+/-SE) of a second cancer at 50 years after diagnosis was 51.0% (+/-6.2%) for hereditary retinoblastoma, and 5.0% (+/-3.0%) for nonhereditary retinoblastoma. All 114 sarcomas of diverse histologic types occurred in patients with hereditary retinoblastoma. For soft tissue sarcomas, the RRs showed a stepwise increase at all dose categories, and were statistically significant at 10 to 29.9 Gy and 30 to 59.9 Gy. A radiation risk for all sarcomas combined was evident at doses above 5 Gy, rising to 10.7-fold at doses of 60 Gy or greater (P<.05). CONCLUSIONS: Genetic predisposition has a substantial impact on risk of subsequent cancers in retinoblastoma patients, which is further increased by radiation treatment. A radiation dose-response relationship is demonstrated for all sarcomas and, for the first time in humans, for soft tissue sarcomas. Retinoblastoma patients should be examined for new cancers and followed into later life to determine whether their extraordinary cancer risk extends to common cancers of adulthood.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma
Dalgard et al.
Clin. Cancer Res. 2008;14:3113-3123.
ABSTRACT | FULL TEXT  

Subconjunctival Topotecan in Fibrin Sealant in the Treatment of Transgenic Murine Retinoblastoma
Tsui et al.
IOVS 2008;49:490-496.
ABSTRACT | FULL TEXT  

Retinoblastoma: Review of Current Management
Chintagumpala et al.
The Oncologist 2007;12:1237-1246.
ABSTRACT | FULL TEXT  

Treatment-Adjusted Predisposition to Second Malignant Neoplasms After a Solid Cancer in Childhood: A Case-Control Study
Guerin et al.
JCO 2007;25:2833-2839.
ABSTRACT | FULL TEXT  

Risk of Soft Tissue Sarcomas by Individual Subtype in Survivors of Hereditary Retinoblastoma
Kleinerman et al.
JNCI J Natl Cancer Inst 2007;99:24-31.
ABSTRACT | FULL TEXT  

Tobacco Use in Adult Long-term Survivors of Retinoblastoma.
Foster et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:1464-1468.
ABSTRACT | FULL TEXT  

Abnormal gene expression profiles in unaffected parents of patients with hereditary-type retinoblastoma.
Chuang et al.
Cancer Res. 2006;66:3428-3433.
ABSTRACT | FULL TEXT  

What are the risks from medical X-rays and other low dose radiation?
Wall et al.
Br. J. Radiol. 2006;79:285-294.
ABSTRACT | FULL TEXT  

Case 5-2006 -- An 11-Year-Old Girl with Loss of Vision in the Right Eye
Walton et al.
NEJM 2006;354:741-748.
FULL TEXT  

Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma
Tong et al.
Br. J. Ophthalmol. 2005;89:1217-1220.
ABSTRACT | FULL TEXT  

Soft-Tissue Sarcomas in Adults
Clark et al.
NEJM 2005;353:701-711.
FULL TEXT  

Increased Risk of Cancer among Siblings of Long-term Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study
Friedman et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1922-1927.
ABSTRACT | FULL TEXT  

Retinoblastoma in the 20th Century: Past Success and Future Challenges The Weisenfeld Lecture
Abramson
IOVS 2005;46:2684-2691.
FULL TEXT  

Second Primary Cancers After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma: COMS Report No. 25
Collaborative Ocular Melanoma Study Group
Arch Ophthalmol 2005;123:601-604.
ABSTRACT | FULL TEXT  

Risk of New Cancers After Radiotherapy in Long-Term Survivors of Retinoblastoma: An Extended Follow-Up
Kleinerman et al.
JCO 2005;23:2272-2279.
ABSTRACT | FULL TEXT  

Cyclosporin A Inhibits Calcineurin/Nuclear Factor of Activated T-Cells Signaling and Induces Apoptosis in Retinoblastoma Cells
Eckstein et al.
IOVS 2005;46:782-790.
ABSTRACT | FULL TEXT  

Cancer Survivorship--Pediatric Issues
Bhatia
ASH Education Book 2005;2005:507-515.
ABSTRACT | FULL TEXT  

Regarding Chemoreduction for Retinoblastoma and Intracranial Neoplasms
Meadows and Shields
Arch Ophthalmol 2004;122:1570-1571.
FULL TEXT  

Outcome Following Initial External Beam Radiotherapy in Patients With Reese-Ellsworth Group Vb Retinoblastoma
Abramson et al.
Arch Ophthalmol 2004;122:1316-1323.
ABSTRACT | FULL TEXT  

For Whom the Bell Tolls: Susceptibility to Common Adult Cancers in Retinoblastoma Survivors
Kaye and Harbour
JNCI J Natl Cancer Inst 2004;96:342-343.
FULL TEXT  

Lifetime Risks of Common Cancers Among Retinoblastoma Survivors
Fletcher et al.
JNCI J Natl Cancer Inst 2004;96:357-363.
ABSTRACT | FULL TEXT  

Rapid Identification of Germline Mutations in Retinoblastoma by Protein Truncation Testing
Tsai et al.
Arch Ophthalmol 2004;122:239-248.
ABSTRACT | FULL TEXT  

Second Malignancies in Pediatric Patients: Imaging Findings and Differential Diagnosis
Vazquez et al.
RadioGraphics 2003;23:1155-1172.
ABSTRACT | FULL TEXT  

Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin
Rodriguez-Galindo et al.
JCO 2003;21:2019-2025.
ABSTRACT | FULL TEXT  

Postenucleation Adjuvant Therapy in High-Risk Retinoblastoma
Honavar et al.
Arch Ophthalmol 2002;120:923-931.
ABSTRACT | FULL TEXT  

(Neonatal) Retinoblastoma in the First Month of Life
Abramson et al.
Arch Ophthalmol 2002;120:738-742.
ABSTRACT | FULL TEXT  

Mushroom-Shaped Choroidal Recurrence of Retinoblastoma 25 Years After Therapy
Shields et al.
Arch Ophthalmol 2002;120:844-846.
FULL TEXT  

A T to C mutation in the polypyrimidine tract of the exon 9 splicing site of the RB1 gene responsible for low penetrance hereditary retinoblastoma
Lefevre et al.
J. Med. Genet. 2002;39:e21-21.
FULL TEXT  

Second Malignant Neoplasms in Five-Year Survivors of Childhood Cancer: Childhood Cancer Survivor Study
Neglia et al.
JNCI J Natl Cancer Inst 2001;93:618-629.
ABSTRACT | FULL TEXT  

Hereditary Retinoblastoma and Risk of Lung Cancer
Kleinerman et al.
JNCI J Natl Cancer Inst 2000;92:2037-2039.
FULL TEXT  

Radiation carcinogenesis
Little
Carcinogenesis 2000;21:397-404.
ABSTRACT | FULL TEXT  

Chemoreduction and Local Ophthalmic Therapy for Intraocular Retinoblastoma
Friedman et al.
JCO 2000;18:12-12.
ABSTRACT | FULL TEXT  

External Beam Radiotherapy in Retinoblastoma: Tumor Control and Comparison of 2 Techniques
Scott et al.
Arch Ophthalmol 1999;117:766-770.
ABSTRACT | FULL TEXT  

Cancer Control in Susceptible Groups: Opportunities and Challenges
Li
JCO 1999;17:719-719.
ABSTRACT | FULL TEXT  

The Outcome of Chemoreduction Treatment in Patients With Reese-Ellsworth Group V Retinoblastoma
Gunduz et al.
Arch Ophthalmol 1998;116:1613-1617.
ABSTRACT | FULL TEXT  

Special JAMA Highlights Genetic Revolution
Journal Watch Dermatology 1997;1997:16-16.
FULL TEXT  

SPECIAL JAMA ISSUE HIGHLIGHTS GENETIC MEDICINE REVOLUTION
JWatch General 1997;1997:7-7.
FULL TEXT